Skeletal Radiology

, Volume 48, Issue 1, pp 119–127 | Cite as

Imaging features of phosphaturic mesenchymal tumors

  • Stephen M. Broski
  • Andrew L. Folpe
  • Doris E. WengerEmail author
Scientific Article



To examine the CT and MR imaging features of phosphaturic mesenchymal tumors (PMTs).

Materials and methods

With IRB approval, our institutional radiology/pathology database was reviewed for pathologically-proven PMTs. CT and MRI examinations were reviewed in consensus noting several imaging features, and if available, comparative molecular imaging tests were analyzed.


We identified 39 patients (21 male, 18 females) with 40 PMTs [mean age, 52.9 ± 14.9 years (range, 14–78)], including 20 bone and 20 soft tissue lesions. Mean maximal lesion diameter was 3.4 ± 2.0 cm (range, 1.1–9.8). 12/18 primary bone lesions (66.6%) were osteolytic and 15/20 (75.0%) had a narrow zone of transition. Internal matrix was present in 18/32 (56.3%) lesions. PMTs were most commonly T1 isointense (31/37, 83.8%), T2 hyperintense (14/36, 38.9%), and solidly enhancing (21/30, 70.0%). The majority (32/36, 88.9%) contained areas of dark T2 signal. 8/9 PMTs were positive by 99mTc-sestamibi scintigraphy, 2/4 by 111In-pentetreotide scintigraphy, 2/2 by 68Ga-DOTATATE PET/CT and 11/13 by 18F-FDG PET/CT. On FDG PET/CT, the mean SUVmax was 4.1 ± 2.5 (range, 1.5–10.8).


Osseous PMTs are commonly osteolytic with a narrow zone of transition. Both bone and soft tissue PMTs often contain matrix and areas of dark T2 signal on MRI, independent of the presence of matrix. However, PMTs may mimic other bone and soft tissue neoplasms, including fibrous dysplasia, tenosynovial giant cell tumor, and even atypical lipomatous tumor. As such, clinical presentation and laboratory correlation are critical to PMT recognition and accurate diagnosis.


PMT Phosphaturic mesenchymal tumor CT MRI PET/CT 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

The need for informed consent was waived by the Institutional Review Board.


  1. 1.
    Kumar R, Folpe AL, Mullan BP. Tumor-induced osteomalacia. Transl Endocrinol Metab 2015;7(3):1871.Google Scholar
  2. 2.
    McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16:33–46.PubMedGoogle Scholar
  3. 3.
    Prader A, Illig R, Uehlinger RE, Stalder G. Rachitis infolge knochentumors (rickets caused by bone tumors). Helv Pediatr Acta. 1959;14:554–65.Google Scholar
  4. 4.
    Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Sundaram M, McCarthy EF. Oncogenic osteomalacia. Skelet Radiol. 2000;29(3):117–24.CrossRefGoogle Scholar
  6. 6.
    Evans DJ, Azzopardi JG. Distinctive tumours of bone and soft tissue causing acquired vitamin-D-resistant osteomalacia. Lancet. 1972;1(7746):353–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer. 1987;59(8):1442–54.CrossRefPubMedGoogle Scholar
  8. 8.
    CDM F. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press; 2013.Google Scholar
  9. 9.
    Gardner KH, Shon W, Folpe AL, Wieland CN, Tebben PJ, Baum CL. Tumor-induced osteomalacia resulting from primary cutaneous phosphaturic mesenchymal tumor: a case and review of the medical literature. J Cutan Pathol. 2013;40(9):780–4. quiz 779CrossRefPubMedGoogle Scholar
  10. 10.
    Woo VL, Landesberg R, Imel EA, Singer SR, Folpe AL, Econs MJ, et al. Phosphaturic mesenchymal tumor, mixed connective tissue variant, of the mandible: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108(6):925–32.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Agrawal K, Bhadada S, Mittal BR, Shukla J, Sood A, Bhattacharya A, et al. Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia. Clin Nucl Med. 2015;40(1):e6–e10.CrossRefPubMedGoogle Scholar
  12. 12.
    Clifton-Bligh RJ, Hofman MS, Duncan E, Sim Ie W, Darnell D, Clarkson A, et al. Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab. 2013;98(2):687–94.CrossRefPubMedGoogle Scholar
  13. 13.
    Ho CL. Ga68-DOTA peptide PET/CT to detect occult mesenchymal tumor-inducing osteomalacia: a case series of three patients. Nucl Med Mol Imaging. 2015;49(3):231–6.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Jadhav S, Kasaliwal R, Lele V, Rangarajan V, Chandra P, Shah H, et al. Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor-based functional scans: a series of nine patients. Clin Endocrinol. 2014;81(1):31–7.CrossRefGoogle Scholar
  15. 15.
    Zhang J, Zhu Z, Zhong D, Dang Y, Xing H, Du Y, et al. 68Ga DOTATATE PET/CT is an accurate imaging modality in the detection of culprit tumors causing osteomalacia. Clin Nucl Med. 2015;40(8):642–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Duet M, Kerkeni S, Sfar R, Bazille C, Liote F, Orcel P. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med. 2008;33(11):752–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Garcia CA, Spencer RP. Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report. Clin Nucl Med. 2002;27(8):582–3.CrossRefPubMedGoogle Scholar
  18. 18.
    Jan de Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet. 2002;359(9308):761–3.CrossRefPubMedGoogle Scholar
  19. 19.
    Nguyen BD, Wang EA. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med. 1999;24(2):130–1.CrossRefPubMedGoogle Scholar
  20. 20.
    Rhee Y, Lee JD, Shin KH, Lee HC, Huh KB, Lim SK. Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin Endocrinol. 2001;54(4):551–4.CrossRefGoogle Scholar
  21. 21.
    Chong WH, Andreopoulou P, Chen CC, Reynolds J, Guthrie L, Kelly M, et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res. 2013;28(6):1386–98.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hodgson SF, Clarke BL, Tebben PJ, Mullan BP, Cooney WP 3rd, Shives TC. Oncogenic osteomalacia: localization of underlying peripheral mesenchymal tumors with use of Tc 99m sestamibi scintigraphy. Endocr Pract. 2006;12(1):35–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Andreopoulou P, Dumitrescu CE, Kelly MH, Brillante BA, Cutler Peck CM, Wodajo FM, et al. Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res. 2011;26(6):1295–302.CrossRefPubMedGoogle Scholar
  24. 24.
    Dupond JL, Mahammedi H, Prie D, Collin F, Gil H, Blagosklonov O, et al. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone. 2005;36(3):375–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Jiang Y, Xia WB, Xing XP, Silva BC, Li M, Wang O, et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res. 2012;27(9):1967–75.CrossRefPubMedGoogle Scholar
  26. 26.
    Koplas MC, Rubin BP, Sundaram M. Phosphaturic mesenchymal tumor: two contrasting cases. Skelet Radiol. 2014;43(6):841–5.CrossRefGoogle Scholar
  27. 27.
    Nakanishi K, Sakai M, Tanaka H, Tsuboi H, Hashimoto J, Hashimoto N, et al. Whole-body MR imaging in detecting phosphaturic mesenchymal tumor (PMT) in tumor-induced hypophosphatemic osteomalacia. Magn Reson Med Sci. 2013;12(1):47–52.CrossRefPubMedGoogle Scholar
  28. 28.
    Avila NA, Skarulis M, Rubino DM, Doppman JL. Oncogenic osteomalacia: lesion detection by MR skeletal survey. AJR Am J Roentgenol. 1996;167(2):343–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Nelson AE, Mason RS, Robinson BG, Hogan JJ, Martin EA, Ahlstrom H, et al. Diagnosis of a patient with oncogenic osteomalacia using a phosphate uptake bioassay of serum and magnetic resonance imaging. Eur J Endocrinol. 2001;145(4):469–76.CrossRefPubMedGoogle Scholar
  30. 30.
    Seo HJ, Choi YJ, Kim HJ, Jeong YH, Cho A, Lee JH, et al. Using (18)F-FDG PET/CT to detect an occult mesenchymal tumor causing oncogenic osteomalacia. Nucl Med Mol Imaging. 2011;45(3):233–7.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Dissanayake AM, Wilson JL, Holdaway IM, Reid IR. Oncogenic osteomalacia: culprit tumour detection whole-body magnetic resonance imaging. Intern Med J. 2003;33(12):615–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Bahrami A, Weiss SW, Montgomery E, Horvai AE, Jin L, Inwards CY, et al. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol. 2009;33(9):1348–54.CrossRefPubMedGoogle Scholar
  33. 33.
    Flanagan AM, Delaney D, O'Donnell P. Benefits of molecular pathology in the diagnosis of musculoskeletal disease: part II of a two-part review: bone tumors and metabolic disorders. Skelet Radiol. 2010;39(3):213–24.CrossRefGoogle Scholar
  34. 34.
    Slot-Steenks MM, Hamdy NA, van de Sande MA, Vriens D, Cleven AH, Appelman-Dijkstra NM. Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma. Endocrine. 2016;54(3):642–7.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Agaimy A, Michal M, Chiosea S, Petersson F, Hadravsky L, Kristiansen G, et al. Phosphaturic mesenchymal tumors: clinicopathologic, immunohistochemical and molecular analysis of 22 cases expanding their morphologic and immunophenotypic spectrum. Am J Surg Pathol. 2017;41(10):1371–80.CrossRefPubMedGoogle Scholar
  36. 36.
    Houang M, Clarkson A, Sioson L, Elston MS, Clifton-Bligh RJ, Dray M, et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol. 2013;44(12):2711–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, et al. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone. 2014;64:222–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Jagtap VS, Sarathi V, Lila AR, Malhotra G, Sankhe SS, Bandgar T, et al. Tumor-induced osteomalacia: a single center experience. Endocr Pract. 2011;17(2):177–84.CrossRefPubMedGoogle Scholar
  39. 39.
    Sent-Doux KN, Mackinnon C, Lee JC, Folpe AL, Habeeb O. Phosphaturic mesenchymal tumor without osteomalacia: additional confirmation of the “non-phosphaturic” variant, with emphasis on the roles of FGF23 chromogenic in situ hybridization and FN1-FGFR1 fluorescence in situ hybridization. Hum Pathol. 2018. Scholar

Copyright information

© ISS 2018

Authors and Affiliations

  1. 1.Department of RadiologyMayo ClinicRochesterUSA
  2. 2.Department of Laboratory Medicine and PathologyMayo ClinicRochesterUSA

Personalised recommendations